Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Buckley

Showing results (1041-1050 of 1,079) with videos related to

Pageof 108
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 4, 2021
Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individualsLiu Shi, Colin R Buchanan, Simon R Cox, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing propertiesN H Lin, D E Gunn, K B Ryther, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 25, 2013
Investigation and management of an outbreak of Salmonella Typhimurium DT8 associated with duck eggs, Ireland 2009 to 2011P Garvey, P McKeown, P Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|June 29, 2001
Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading methodS K Kang, R H Chou, R K Dodge, et al.
Journal of Medicinal Chemistry|March 4, 1998
Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptorsM W Holladay, J T Wasicak, N H Lin, et al.
Annals of Clinical and Translational Neurology|January 19, 2019
Novel pathogenic <i>COX20</i> variants causing dysarthria, ataxia, and sensory neuropathyMaria G Otero, Emmanuelle Tiongson, Frank Diaz, et al.
Neuroscience and Biobehavioral Reviews|September 1, 2020
Diagnostic biomarkers for obsessive-compulsive disorder: A reasonable quest or ignis fatuus?Miquel A Fullana, Amitai Abramovitch, Esther Via, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
PAI-1 Deficiency Drives Pulmonary Vascular Smooth Muscle Remodeling and Pulmonary HypertensionTatiana V Kudryashova, Sergei Zaitsev, Lifeng Jiang, et al.
CNS Drug Reviews|June 5, 2004
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disordersLynne E Rueter, David J Anderson, Clark A Briggs, et al.
Lancet (London, England)|November 26, 2015
Exploring the evidence base for national and regional policy interventions to combat resistanceOsman A Dar, Rumina Hasan, Jørgen Schlundt, et al.
Pageof 108

Showing results (1041-1050 of 1,079) with videos related to

Sort By:
Pageof 108
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 4, 2021
Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individualsLiu Shi, Colin R Buchanan, Simon R Cox, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing propertiesN H Lin, D E Gunn, K B Ryther, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 25, 2013
Investigation and management of an outbreak of Salmonella Typhimurium DT8 associated with duck eggs, Ireland 2009 to 2011P Garvey, P McKeown, P Kelly, et al.
International Journal of Radiation Oncology, Biology, Physics|June 29, 2001
Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading methodS K Kang, R H Chou, R K Dodge, et al.
Journal of Medicinal Chemistry|March 4, 1998
Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptorsM W Holladay, J T Wasicak, N H Lin, et al.
Annals of Clinical and Translational Neurology|January 19, 2019
Novel pathogenic <i>COX20</i> variants causing dysarthria, ataxia, and sensory neuropathyMaria G Otero, Emmanuelle Tiongson, Frank Diaz, et al.
Neuroscience and Biobehavioral Reviews|September 1, 2020
Diagnostic biomarkers for obsessive-compulsive disorder: A reasonable quest or ignis fatuus?Miquel A Fullana, Amitai Abramovitch, Esther Via, et al.
Biorxiv : the Preprint Server for Biology|October 4, 2023
PAI-1 Deficiency Drives Pulmonary Vascular Smooth Muscle Remodeling and Pulmonary HypertensionTatiana V Kudryashova, Sergei Zaitsev, Lifeng Jiang, et al.
CNS Drug Reviews|June 5, 2004
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disordersLynne E Rueter, David J Anderson, Clark A Briggs, et al.
Lancet (London, England)|November 26, 2015
Exploring the evidence base for national and regional policy interventions to combat resistanceOsman A Dar, Rumina Hasan, Jørgen Schlundt, et al.
Pageof 108